Adamis Pharmaceuticals (NASDAQ:ADMP) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP) in a research note published on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Price Performance

NASDAQ:ADMP opened at $0.78 on Monday. Adamis Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $26.18. The firm has a 50 day simple moving average of $1.45 and a 200-day simple moving average of $4.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adamis Pharmaceuticals stock. Armistice Capital LLC bought a new position in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,500,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,681,000. Armistice Capital LLC owned 8.71% of Adamis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 38.55% of the stock is owned by institutional investors.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.